Treatment of hormone-resistant prostate cancer can be a challenging situation. The first important step in treating this condition is to assess if one has achieved the castrate level or not. If the castrate levels are not achieved, attempt should be made to achieve so. If the castrate level is achieved, then androgen withdrawals may be of help. Supportive care, care of the clinical problems forms an integral part of the treatment. Cancer-specific chemotherapy is certainly an option in progressive disease
Prostate cancer is the most frequently diagnosed cancer in humans. An estimated 189000 men will be d...
This review is dedicated to the impact of modern achievements on the definition and diagnostics of c...
Managing optimal health in castrate-resistant prostate cancer is a complex clinical challenge. Quali...
After an average of 18-36 months under androgen suppression therapy by surgical castration, LHRH, an...
Prostate cancer is the most common malignancy in males and, despite a marked improvement in diagnost...
Prostate cancer relies on signaling through the androgen receptor (AR) for maintenance and progressi...
I discuss treatment possibilities of prostate cancers that don't respond to the hormonal deprivation...
Prostate cancer is one of the most common urological malignancies. Improved diagnostic methods and w...
Prostate cancer is the most common form of cancer in men in the Western world. One-third of the pati...
Men receiving androgen-deprivation therapy will in time develop metastatic castrate-resistant prosta...
The therapeutic landscape of castration-resistant prostate cancer (CRPC) has changed dramatically in...
Men receiving androgen-deprivation therapy will in time develop metastatic castrate-resistant prosta...
<p>Hormone therapy is a basic treatment for locally advanced and/or metastatic prostate cancer (PC);...
To develop a clinical practice guideline for the management of men with metastatic, recurrent, or pr...
Background: Guidelines on the clinical management of non-metastatic castrate-resistant prostate canc...
Prostate cancer is the most frequently diagnosed cancer in humans. An estimated 189000 men will be d...
This review is dedicated to the impact of modern achievements on the definition and diagnostics of c...
Managing optimal health in castrate-resistant prostate cancer is a complex clinical challenge. Quali...
After an average of 18-36 months under androgen suppression therapy by surgical castration, LHRH, an...
Prostate cancer is the most common malignancy in males and, despite a marked improvement in diagnost...
Prostate cancer relies on signaling through the androgen receptor (AR) for maintenance and progressi...
I discuss treatment possibilities of prostate cancers that don't respond to the hormonal deprivation...
Prostate cancer is one of the most common urological malignancies. Improved diagnostic methods and w...
Prostate cancer is the most common form of cancer in men in the Western world. One-third of the pati...
Men receiving androgen-deprivation therapy will in time develop metastatic castrate-resistant prosta...
The therapeutic landscape of castration-resistant prostate cancer (CRPC) has changed dramatically in...
Men receiving androgen-deprivation therapy will in time develop metastatic castrate-resistant prosta...
<p>Hormone therapy is a basic treatment for locally advanced and/or metastatic prostate cancer (PC);...
To develop a clinical practice guideline for the management of men with metastatic, recurrent, or pr...
Background: Guidelines on the clinical management of non-metastatic castrate-resistant prostate canc...
Prostate cancer is the most frequently diagnosed cancer in humans. An estimated 189000 men will be d...
This review is dedicated to the impact of modern achievements on the definition and diagnostics of c...
Managing optimal health in castrate-resistant prostate cancer is a complex clinical challenge. Quali...